ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.

ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.

The study was to estimate the likelihood of axillary downstaging and to identify the factors predicting a pathologically node negative status after neoadjuvant chemotherapy (NAC) with or without trastuzumab in HER2-positive breast cancer.Patients with HER2-positive, stage IIa-IIIc breast cancer were...

Full description

Bibliographic Details
Main Authors: Jian-Wei Li, Miao Mo, Ke-da Yu, Can-Ming Chen, Zhen Hu, Yi-Feng Hou, Gen-Hong Di, Jiong Wu, Zhen-Zhou Shen, Zhi-Ming Shao, Guang-Yu Liu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4263615?pdf=render

Similar Items

Similar Items